-white.png)
RPR™ Resources
Since 2016, MAT has run close to 700 projects across 45 countries on the RPR platform. Learn about how we have helped our clients expand and deepen their insights - gathering feedback from our global payer network to inform pivotal product development decisions across a range of treatment areas and phases.
RPR in action
Robust Reviews explore a variety of situations where global pharmaceutical and device manufacturers have leveraged RPR instead of traditional payer research methods. These case studies span treatment areas, development phases, and markets. Interested in learning more? Contact us and a member of our Commercial team will be in touch.
Surrogate Endpoints
Payers provide a deep understanding of the acceptability of surrogate end-points
​Download >
Pricing & Market Access
Gaining invaluable Payer insight into Pricing and Access acceptability
Multi-Indication Prioritization
Leveraging Rapid Payer Response™ (RPR) to prioritize an asset's commercial opportunity across multiple indications in Acute
Evidence Generation Plan
Invaluable payer insight into a TPP and the design for an evidence generation
White Papers
Comprehensive reports spanning multiple payer research initiatives give broad insight into trends and themes across the market access landscape
Achieving Early Access in Oncology with Non-Comparative Data:
How HTAs approach single arm trial evidence in oncology
Achieving Early Access in Oncology with Non-Comparative Data:
Drivers and resistors of acceptance of single arm data
Seen at ISPOR
Approved posters from previous ISPOR conferences
ISPOR Europe 2022
Payer perspectives on the impact of the COVID-19 pandemic on health technology assessments (HTA) in Europe
ISPOR Europe 2019
Assessing the evolution of the pricing and access landscape for cell and gene therapies in the US and EU3 through a web-based portal to engage payers
ISPOR Europe 2022
Identifying the key challenges in the reimbursement of next generation sequencing and future policy changes in Europe using web-based portal to engage payers
ISPOR Europe 2018
Identifying the key drivers affecting the reimbursement of therapeutic vaccines in the EU5 using web-based portal to engage payers
ISPOR Europe 2019
Value-based procurement: Understanding how payers approach and implement contracting and procurement of novel treatments based on their value
ISPOR Europe 2018
Understanding the impact of real world evidence on reimbursement decisions across EU5 countries using a web-based portal to engage payers
ISPOR Europe 2019
Identifying the key challenges in evaluation and pricing of oncology combination therapies and future policy changes using a web-based portal to engage payers
ISPOR Europe 2018
Identifying the key challenges affecting the reimbursement of CAR-T therapies in the EU5 using a web-based portal to engage payers